title: Excitatory drive from the Subthalamic nucleus attenuates GABAergic transmission in the Substantia Nigra pars compacta via endocannabinoids.
abstract: Endocannabinoids (eCBs) are cannabis-like substances produced in the brain where their primary function is to regulate synaptic transmission by inhibiting neurotransmitter release in a retrograde fashion. We have recently demonstrated a novel mechanism regulating GABAergic transmission from neurons in the Substantia Nigra pars reticulata (SNr) to dopaminergic neurons in the Substantia Nigra pars compacta (SNc) mediated by eCBs. Production of eCBs was initiated by spillover of glutamate, yet the source of the glutamate was not determined (Freestone et al., 2014; Neuropharmacology 79 p467). The present study aimed at elucidating the potential role of glutamatergic terminals arising from neurons in the Subthalamic nucleus (STN) in driving the eCB-mediated modulation of this inhibitory transmission. GABAergic IPSCs or IPSPs evoked in SNc neurons by electrical stimuli delivered to the SNr region were transiently inhibited by electrical or pharmacological (U-tube application of muscarinic agonist carbachol [100 µM]) stimulation of the STN (to 74±5% and 69±4% respectively). In both stimulation protocols, the attenuation of GABAergic transmission was abolished by cannabinoid receptor 1 antagonist rimonabant (3 µM), and reduced by group 1 metabotropic glutamate receptor antagonist CPCCOEt (100 µM), consistent with a glutamate-initiated and eCB-mediated mechanism. The carbachol-induced attenuation of GABAergic transmission was abolished by M3 muscarinic receptor antagonist 4-DAMP (10 µM), confirming a specific activation of STN neurons. These results demonstrate that glutamatergic projection from the STN to dopaminergic SNc neurons underlies an eCB-mediated inhibition of GABAergic input to these neurons.
authors.affiliation: Department of Physiology & Centre for Brain Research, University of Auckland, New Zealand; Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019 Auckland Mail Centre, Auckland 1142, New Zealand. Electronic address: peter.s.freestone@gmail.com.
authors.forename: Peter S
authors.initials: PS
authors.lastname: Freestone
authors.affiliation: Department of Physiology & Centre for Brain Research, University of Auckland, New Zealand; Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019 Auckland Mail Centre, Auckland 1142, New Zealand. Electronic address: xwu073@aucklanduni.ac.nz.
authors.forename: Xi Hau
authors.initials: XH
authors.lastname: Wu
authors.affiliation: Department of Physiology & Centre for Brain Research, University of Auckland, New Zealand; Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019 Auckland Mail Centre, Auckland 1142, New Zealand. Electronic address: gabrielaadg@gmail.com.
authors.forename: Gabriel
authors.initials: G
authors.lastname: de Guzman
authors.affiliation: Department of Physiology & Centre for Brain Research, University of Auckland, New Zealand; Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019 Auckland Mail Centre, Auckland 1142, New Zealand. Electronic address: j.lipski@auckland.ac.nz.
authors.forename: Janusz
authors.initials: J
authors.lastname: Lipski
mesh_terms: D000818:Animals; D002217:Carbachol / Q000037:antagonists & inhibitors / Q000494:pharmacology; D002867:Chromones / Q000008:administration & dosage / Q000494:pharmacology; D059290:Dopaminergic Neurons / Q000502:physiology; D004558:Electric Stimulation; D063388:Endocannabinoids / Q000502:physiology*; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D059330:GABAergic Neurons / Q000187:drug effects / Q000502:physiology*; D053444:Inhibitory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D065842:Pars Compacta / Q000502:physiology*; D065841:Pars Reticulata / Q000187:drug effects / Q000502:physiology; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D000077285:Rimonabant; D020531:Subthalamic Nucleus / Q000187:drug effects / Q000502:physiology*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*
chemical_list: C117789:7-(hydroxyimino)cyclopropan(b)chromen-1a-carbxoylic acid ethyl ester; D002867:Chromones; D063388:Endocannabinoids; D010880:Piperidines; D011720:Pyrazoles; C042375:4-diphenylacetoxy-1,1-dimethylpiperidinium; D002217:Carbachol; D000077285:Rimonabant
keywords: Dopaminergic; Endocannabinoids; Hyperdirect pathway; Substantia Nigra pars compacta; Subthalamic nucleus; Synaptic transmission